The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Updates in early stage non-small cell lung cancer
Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, discusses key updates in early-stage non-small cell lung cancer, higlighting the role of chemotherapy and immunotherapy in the adjuvant and neoadjuvant settings as well as treatment sequencing in patients with actionable mutations. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript
The main highlights are in the field of the early stages, of course, and so trying to explore the role of chemo and the IO in the adjuvant and neoadjuvant treatment. So trying to understand the better sequencing also for patients with oncogenic positive disease, to understand if this combination may be available and active, even in this field. Or if in the early stages, we have to look at only early treatment by oncogenic inhibition...
The main highlights are in the field of the early stages, of course, and so trying to explore the role of chemo and the IO in the adjuvant and neoadjuvant treatment. So trying to understand the better sequencing also for patients with oncogenic positive disease, to understand if this combination may be available and active, even in this field. Or if in the early stages, we have to look at only early treatment by oncogenic inhibition. So these are the major field to look at in the next month.
Read more...
